Drugs / TAS1553
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04637009 | Dec 2020 → Feb 2023 | acute myeloid leukemia, myelodysplastic/myeloproliferative neoplasm | Astex Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAS1553 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04637009 ↗ |
| Modality | Small molecule | — CHEMBL6068624 ↗ |
| Route | Oral | “Route of Administration: oral” NCT04637009 ↗ |